In the last trading session, 1.73 million Macrogenics Inc (NASDAQ:MGNX) shares changed hands as the company’s beta touched 2.17. With the company’s per share price at $1.10 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $69.40M. MGNX’s last price was a discount, traded about -1676.36% off its 52-week high of $19.54. The share price had its 52-week low at $0.99, which suggests the last value was 10.0% up since then. When we look at Macrogenics Inc’s average trading volume, we note the 10-day average is 1.3 million shares, with the 3-month average coming to 733.60K.
Analysts gave the Macrogenics Inc (MGNX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.38. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended MGNX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Macrogenics Inc’s EPS for the current quarter is expected to be -0.69.
Macrogenics Inc (NASDAQ:MGNX) trade information
The company’s shares are showing year-to-date downside of -66.15%, with the 5-day performance at -9.84% in the red. However, in the 30-day time frame, Macrogenics Inc (NASDAQ:MGNX) is -50.78% down. Looking at the short shares, we see there were 4.97 million shares sold at short interest cover period of 8.94 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need an upside of 45.0% from its current market value. According to analyst projections, MGNX’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a -81.82% plunge from its current level, while the stock would need to soar -81.82% for it to hit the projected low.
Macrogenics Inc (MGNX) estimates and forecasts
Year-over-year growth is forecast to reach -58.33% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 9.59M. 6 analysts are of the opinion that Macrogenics Inc’s revenue for the current quarter will be 11.77M. The company’s revenue for the corresponding quarters a year ago was 9.1M and 10.8M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 5.37%. The estimates for the next quarter sales put growth at 8.99%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.47%. The 2025 estimates are for Macrogenics Inc earnings to decrease by -140.19%, but the outlook for the next 5-year period is at -28.62% per year.
MGNX Dividends
Macrogenics Inc is expected to release its next quarterly earnings report on 2025-Mar-19.
Macrogenics Inc (NASDAQ:MGNX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.25% of Macrogenics Inc shares while 93.32% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.46%. There are 93.32% institutions holding the Macrogenics Inc stock share, with BELLEVUE GROUP AG the top institutional holder. As of 2024-06-30, the company held 15.8662% of the shares, roughly 9.94 million MGNX shares worth $42.25 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.5749% or 6.0 million shares worth $25.5 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.42 shares estimated at $2.66 million under it, the former controlled 3.83% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.13% of the shares, roughly 1.97 shares worth around $2.17 million.
